Ptc Therapeutics (PTCT) Gross Margin (2016 - 2026)

Ptc Therapeutics' Gross Margin history runs 11 years deep, the most recent figure standing at 89.72% for Q1 2026.

• On a quarterly basis, Gross Margin fell 919.0% year-over-year to 89.72% in Q1 2026; TTM through Mar 2026 was 92.48%, a 402.0% decrease from a year earlier, with the FY2025 full-year figure at 97.28%, up 440.0% from the prior year.
• Gross Margin retreated to 89.72% in Q1 2026 per PTCT's latest filing, from 95.78% in the prior quarter.
• Across five years, Gross Margin topped out at 98.91% in Q1 2025 and bottomed at 89.72% in Q1 2026.
• The 5-year median for Gross Margin is 93.56% (2022), against an average of 93.63%.
• Across the five-year window, Gross Margin surged 592 bps in 2025 and slumped 919 bps in 2026, its largest moves.
• Year by year, Gross Margin stood at 93.49% in 2022, then decreased by 3 bps to 90.52% in 2023, then grew by 2 bps to 92.36% in 2024, then increased by 4 bps to 95.78% in 2025, then slipped by 6 bps to 89.72% in 2026.
• Per Business Quant, the three latest PTCT Gross Margin figures stand at 89.72% (Q1 2026), 95.78% (Q4 2025), and 92.52% (Q3 2025).